Literature DB >> 1992120

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.

G W Rewcastle1, G J Atwell, Z A Li, B C Baguley, W A Denny.   

Abstract

Analogues of 9-oxo-9H-xanthene-4-acetic acid (XAA) bearing small, lipophilic 5-substituents are among the most dose-potent compounds yet reported with the capability of causing hemorrhagic necrosis of implanted colon 38 tumors in mice. To further extend structure-activity relationships among this class of compound, a series of XAA derivatives bearing two small lipophilic groups at various positions have been prepared and evaluated. The 5,6-disubstituted compounds in particular show consistently high levels of both dose potency and activity, suggesting this is the optimal configuration among substituted 9-oxo-9H-xanthene-4-acetic acids. The 5,6- dimethyl and 5-methyl-6-methoxy are the most effective analogues, showing in vivo colon 38 activity comparable to that of FAA at 10-15-fold lower doses and superior activity to FAA at the respective optimal doses, and the former has been selected for detailed evaluation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992120     DOI: 10.1021/jm00105a034

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets.

Authors:  Cameron S Bader; Henry Barreras; Casey O Lightbourn; Sabrina N Copsel; Dietlinde Wolf; Jingjing Meng; Jeonghyun Ahn; Krishna V Komanduri; Bruce R Blazar; Lei Jin; Glen N Barber; Sabita Roy; Robert B Levy
Journal:  Sci Transl Med       Date:  2020-07-15       Impact factor: 17.956

3.  Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.

Authors:  M E Watts; S Arnold; D J Chaplin
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 4.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Anticancer flavonoids are mouse-selective STING agonists.

Authors:  Sujeong Kim; Lingyin Li; Zoltan Maliga; Qian Yin; Hao Wu; Timothy J Mitchison
Journal:  ACS Chem Biol       Date:  2013-05-23       Impact factor: 5.100

8.  Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.

Authors:  L L Thomsen; B C Baguley; W R Wilson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.